Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria

BACKGROUND: Globally, drug resistant tuberculosis (DR-TB) continues to be a public health threat. Nigeria, which accounts for a significant proportion of the global burden of rifampicin/multi-drug resistant-TB (RR/MDR-TB) had a funding gap of $168 million dollars for TB treatment in 2018. Since 2010...

Descripción completa

Detalles Bibliográficos
Autores principales: Bada, Florence O., Blok, Nick, Okpokoro, Evaezi, Dutt, Saswata, Akolo, Christopher, Dakum, Patrick, Abimiku, Alash’le
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707487/
https://www.ncbi.nlm.nih.gov/pubmed/33259492
http://dx.doi.org/10.1371/journal.pone.0241065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7707487/
https://www.ncbi.nlm.nih.gov/pubmed/33259492
http://dx.doi.org/10.1371/journal.pone.0241065

Ejemplares similares